All News

As always, this month’s edition of Contemporary OB/GYN® features multiple peer-reviewed articles that offer in-depth guidance and analyses of key topics in ob/gyn. Here are the highlights of this special technology-centered issue.

Contemporary OB/GYN® held a panel discussion in September with 4 renowned minimally invasive gynecologic surgeons (MIGS) who discussed vaginal natural orifice transluminal endoscopic surgery (vNOTES).

In this episode, Michael Krychman, MD, sat down with Alyssa Dweck, MD, gynecologist, and Bonafide medical advisor to catch up at this year's North American Menopause Society (NAMS) Annual Meeting.

Prenatal exposure to inorganic arsenic and coexposure to inorganic arsenic and cadmium was found to increase risk of atopic dermatitis by up to 2.42-fold in young Taiwanese children.

An abstract presented at CHEST 2021 showed that women who entered pregnancy with sleep-disordered breathing were associated with higher levels of insulin resistance and potential risk of gestational diabetes.

Socioeconomic and ethnic inequalities among women in England were responsible for adverse pregnancy outcomes such as stillbirths, preterm births, and births with fetal growth restriction, with the largest inequalities among Black and South Asian women.

More medical and SDOH (social determinants of health) data is available now than ever before to clinicians, health care organizations, and payors. Using this data can lead to better outcomes.

Genomic testing has grown in importance as the number of targeted anticancer therapies rises. Early genomic testing can help to guide treatment choices.

The next step in the approval process is the formal acceptance of the recommendation by CDC Director Rochelle P. Walensky, MD, MPH.

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

A recent study indicates that when born prematurely, twins may have some gains over singleton babies.

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

Here's what's coming up this week on Contemporary OB/GYN®

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.

The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.

Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.

Here's what you missed this week on Contemporary OB/GYN®.

Oral contraceptives are not linked to early natural menopause, according to a population-based study in the journal Human Reproduction.

The U.S. Supreme Court has agreed to review Texas’ controversial abortion ban on Nov. 1. However, they refused to block the law during the examination process, during which they will decide whether the Department of Justice has the right to sue to block the law.

Whether you practice in Texas or not, the strict abortion ban may be an influencing factor for many abortion providers.

Medically underserved and minority breast cancer survivors experienced improved outcomes and quality of life after participating in community-based physical activity programs, according to recent study results.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

Patients are looking for user-friendly technology.

Age of first menarche has long been seen as a girl's start to puberty, but breast development may be a better fit.

Here's a preview of what to expect this week from Contemporary OB/GYN®.

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Hospitals should put you in the pink, not in the red.

It's been a busy week for the Contemporary OB/GYN® team.

UnitedHealthcare’s newly launched virtual first plan is one part of a push by the industry.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.